PB2153 MENTAL HEALTH AND QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE

Background: Elotuzumab plus lenalidomide and dexamethasone (ELd) is an important treatment option for the management of patients with relapsed/refractory multiple myeloma (RRMM). This, combined with the well‐established long‐term safety and tolerability profile, supports this regimen as a valuable treatment option offering long‐term benefits to patients with RRMM. Current therapies aim to maintain health‐related quality of life (HRQoL) while prolonging survival. In the ELOQUENT‐2 study, improvements in PFS and ORR were achieved without compromising pain control or diminishing HRQoL, pain scores and HRQoL remaining unaffected over time. However, in clinical practice, there are few reports confirming the influence of the patient's mental state on quality of life while continuing ELd therapy. Aims: The aim of this study was to evaluate the patient's mental state before and after ELd therapy as a mediator of health‐related quality of life. Methods The study population was 15 RRMM patients who would be treated with ELd as a clinical practice. Data were collected from a self‐administered questionnaire and patients’ medical records. We developed an original questionnaire called M‐QoL8 to confirm the patient's condition in clinical practice, not for clinical research. The module comprises eight questions: burden or suffering of visit, the treatment feels effective, want to continue treatment, improve the quality of life, having hope for living, better than pretreatment and feeling that they are healthy. After obtaining informed consent, we assessed QoL of the baseline and 4th cycle after study enrolment. We also assessment of HRQoL using the EORTC QLQ‐C30, QLQ‐MY20. Results: A total of 16 RRMM patients receiving ELd therapy were enrolled between June 2018 and March 2019. Completed questionnaire were received from 15 patients. The median age was 76 years (range;66‐87), and male was dominant (n = 13,81%). We summarized the 11 cases that we could evaluate for the second time and update it at the time of presentation. In the first questionnaire after ELd therapy, the average score of feeling that they are healthy was as high as 8.3 (5‐10) compared with the average score of 6.7 (0‐10) for the treatment feels effective. This tendency was similar in the questionnaire after the addition of 4th cycle, and the average score of hope of continuation of ELd therapy was maintained at 7.8 to 8.2. Summary/Conclusion: In RRMM patients who cannot expect cure, an important goal for continuing treatment is to maintain quality of life, with patients feeling that they are healthy, and having hope for living. As a result of comparison before and after the start of ELd therapy, many patients report that they are maintaining their health. Using simple questions in the M‐QoL8 to evaluate mental and emotional quality of life, it is possible to evaluate these important aspects of health before and after ELd treatment.